Artemisinins for schistosomiasis and beyond

Current Opinion in Investigational Drugs

Volumn 8, Issue 2, 2007, Pages 105-116

  Utzinger, Jürg ^a   Shu Hua, Xiao ^b   Tanner, Marcel ^a   Keiser, Jennifer ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Artemether; Artemisinin; Artemisinin based combination therapy; Artesunate; Food borne trematodiasis; Schistosomiasis

Indexed keywords

AMODIAQUINE; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; DIHYDROARTEMISININ; PLACEBO; PRAZIQUANTEL; SULFADOXINE; TRICLABENDAZOLE;

ABDOMINAL PAIN; ANTIMALARIAL ACTIVITY; CANCER; CANCER CELL; CLINICAL TRIAL; CONSTIPATION; COUGHING; CYTOTOXICITY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; HEMATOCHEZIA; HUMAN; LIFE CYCLE; MALARIA; MORBIDITY; MORTALITY; NAUSEA AND VOMITING; PATHOGENICITY; PLASMODIUM; PRURITUS; REVIEW; SCANNING ELECTRON MICROSCOPY; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMIASIS; SINGLE DRUG DOSE; TRANSMISSION ELECTRON MICROSCOPY; TREMATODE; TREMATODIASIS;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUGS, INVESTIGATIONAL; HUMANS; MOLECULAR STRUCTURE; SCHISTOSOMIASIS;

EID: 33947318791     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Ross AGP, Bartley PM, Sleigh AC, Olds GR, Li YS, Williams GM, McManus DP: Schistosomiasis. N Engl J Med (2002) 346(16):1212-1220.
2. Davis A: Schistosomiasis. In: Manson's Tropical Diseases. Cook GC, Zumla AI (Eds), 21st Edition, Saunders Ltd, Oxford, UK (2002):1431-1469. •• A comprehensive book chapter covering all aspects of the epidemiology and control of schistosomiasis.
3. Gryseels B, Polman K, Clerinx J, Kestens L: Human schistosomiasis. Lancet (2006) 368(9541):1106-1118. • Good up-to-date review of human schistosomiasis, covering the life cycle, epidemiology, and the diagnosis and treatment of the disease.
4. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD: Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med (2006) 3(5):e102. •• A landmark paper that put the NTDs on the political radar screen, proposing integrated chemotherapy as one of the best options for public-health.
5. Engels D, Savioli L: Reconsidering the underestimated burden caused by neglected tropical diseases. Trends Parasitol (2006) 22(8):363-366.
6. Hotez P, Ottesen E, Fenwick A, Molyneux D: The neglected tropical diseases: The ancient afflictions of stigma and poverty and the prospects for their control and elimination. Adv Exp Med Biol (2006) 582:23-33.
7. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL: Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet (2006) 367(9524):1747-1757.
8. Raso G, Vounatsou P, Singer BH, N'Goran EK, Tanner M, Utzinger J: An integrated approach for risk profiling and spatial prediction of Schistosoma mansoni-hookworm coinfection. Proc Natl Acad Sci USA (2006) 103(18):6934-6939. •• This study is the first to attempt the mapping and prediction of S mansoni hookworm co-infection, which in turn is critical for spatial targeting of control.
9. Brady MA, Hooper PJ, Ottesen EA: Projected benefits from integrating NTD programs in sub-Saharan Africa. Trends Parasitol (2006) 22(7):285-291.
10. Lammie PJ, Fenwick A, Utzinger J: A blueprint for success: Integration of neglected tropical disease control programmes. Trends Parasitol (2006) 22(7):313-321. •• This review discusses progress in the control of schistosomiasis, soil-transmitted helminthiasis and lymphatic filariasis, including the challenges faced as the integration of NTD control programs proceeds.
11. Richards FO Jr, Eigege A, Miri ES, Jinadu MY, Hopkins DR: Integration of mass drug administration programmes in Nigeria: The challenge of schistosomiasis. Bull World Health Organ (2006) 84(8):673-676.
12. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J: Schistosomiasis and water resources development: Systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis (2006) 6(7):411-425.
13. WHO: Prevention and control of schistosomiasis and soil-transmitted helminthiasis: Report of a WHO expert committee. WHO Tech Rep Ser (2002):912. •• An important report from the WHO, proposing the integration of schistosomiasis and soil-transmitted helminthiasis control.
14. The world health report 2004: Changing history. World Health Organization, Geneva, Switzerland (2004). http://www.who.int/whr/2004/en/ report04_en.pdf
15. King CH, Dickman K, Tisch DJ: Reassessment of the cost of chronic helmintic infection: A meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet (2005) 365(9470):1561-1569. •• An excellent paper making the compelling case that the burden of schistosomiasis has been significantly underestimated.
16. Engels D, Chitsulo L, Montresor A, Savioli L: The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop (2002) 82(2):139-146.
17. Utzinger J, Zhou XN, Chen MG, Bergquist R: Conquering schistosomiasis in China: The long march. Acta Trop (2005) 96(2-3):69-96. • A comprehensive review of schistosomiasis research and disease control undertaken over the past 50 years in China.
18. Fenwick A, Rollinson D, Southgate V: Implementation of human schistosomiasis control: Challenges and prospects. Adv Parasitol (2006) 61:567-622. • A useful paper covering the history of schistosomiasis, methods of controlling the disease and the development of drugs targeting adult worms.
19. Giles J: Tide of censure for African dams. Nature (2006) 440(7083):393-394.
20. Seubert J, Pohlke R, Loebich F: Synthesis and properties of praziquantel, a novel broad spectrum antihelmintic with excellent activity against schistosomes and cestodes. Experientia (1977) 33(8):1036-1037.
21. Groll E: Praziquantel. Adv Pharmacol Chemother (1984) 20:219-238.
22. Cioli D, Pica-Mattoccia L, Archer S: Antischistosomal drugs: Past, present ... and future? Pharmacol Ther (1995) 68(1):35-85. •• One of the best and most comprehensive reviews covering antischistosomal drug discovery and development. It focuses on the mechanisms of action of these drugs and the need for new drugs against this parasite.
23. WHO: The control of schistosomiasis: Report of a WHO expert committee. WHO Tech Rep Ser (1985):728.
24. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH: Drugs for the control of parasitic diseases: Current status and development in schistosomiasis. Trends Parasitol (2003) 19(11):509-515.
25. Chen MG: Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: A review of 30 years' experience. Acta Trop (2005) 96(2-3):168-176.
26. Cioli D: Chemotherapy of schistosomiasis: An update. Parasitol Today (1998) 14(10):418-422.
27. Utzinger J, Keiser J: Schistosomiasis and soil-transmitted helminthiasis: Common drugs for treatment and control. Expert Opin Pharmacother (2004) 5(2):263-285. •• A comprehensive review of the drugs currently available for the treatment and control of schistosomiasis and soil-transmitted helminthiasis, including the discovery, chemistry, pharmacological properties, therapeutic efficacy and adverse effects of those drugs in clinical use.
28. Xiao SH, Booth M, Tanner M: The prophylactic effects of artemether against Schistosoma japonicum infections. Parasitol Today (2000) 16(3):122-126.
29. Utzinger J, Xiao SH, Keiser J, Chen MG, Zheng J, Tanner M: Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr Med Chem (2001) 8(15):1841-1860.
30. Utzinger J, Xiao SH, N'Goran EK, Berqquist R, Tanner M: The potential of artemether for the control of schistosomiasis. Int J Parasitol (2001) 31(14):1549-1562.
31. Xiao SH, Tanner M, N'Goran EK, Utzinger J, Chollet J, Bergquist R, Chen MG, Zheng J: Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop (2002) 82(2):175-181.
32. Utzinger J, Keiser J, Xiao SH, Tanner M, Singer BH: Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials. Antimicrob Agents Chemother (2003) 47(5):1487-1495.
33. Xiao SH: Development of antischistosomal drugs in China, with particular consideration to praziquantel and the artemisinins. Acta Trop (2005) 96(2-3):153-167.
34. Wang TP, Vang Johansen M, Zhang SQ, Wang FF, Wu WD, Zhang GH, Pan XP, Ju Y, Ørnbjerg N: Transmission of Schistosoma japonicum by humans and domestic animals in the Yangtze River valley, Anhui province, China. Acta Trop (2005) 96(2-3):198-204.
35. Clegg JA: In vitro cultivation of Schistosoma mansoni. Exp Parasitol (1965) 16:133-147.
36. Ghandour AM: The development of Schistosoma haematobium in the hamster. Ann Trop Med Parasitol (1978) 72(3):219- 225.
37. Smith M, Clegg JA, Webbe G: Culture of Schistosoma haematobium in vivo and in vitro. Ann Trop Med Parasitol (1976) 70(1):101-107.
38. Colley DG, Evan Secor W: Immunoregulation and World Health Assembly resolution 54.19: Why does treatment control morbidity? Parasitol Int (2004) 53(2):143-150.
39. Fenwick A, Keiser J, Utzinger J: Epidemiology, burden and control of schistosomiasis with particular consideration to past and current treatment trends. Drugs Fut (2006) 31(5):413-425.
40. van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, Engels D: Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop (2003) 86(2-3):125-139. •• An important paper which estimates the annual mortality rates from schistosomiasis in Africa. This study estimated the numbers of individuals with disease-specific morbidity for S haematobium and S mansoni infection in sub-Saharan Africa.
41. Bergquist NR, Leonardo LR, Mitchell GF: Vaccine-linked chemotherapy: Can schistosomiasis control benefit from an integrated approach? Trends Parasitol (2005) 21(3):112-117.
42. Jordan P: From Katayama to the Dakhla Oasis: The beginning of epidemiology and control of bilharzia. Acta Trop (2000) 77(1):9-40. •• This paper provides an array of interesting historical material, including the controversies and theories that preceded the unravelling of the schistosome life cycle.
43. Christopherson JB: The successful use of antimony in bilharziosis administered as intravenous injections of ammonium tartaratum (tartar emetic). Lancet (1918) 192(4958):325-327.
44. Davis A, Biles JE, Ulrich AM: Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull World Health Organ (1979) 57(5):773-779.
45. Katz N, Rocha RS, Chaves A: Preliminary trials with praziquantel in human infections due to Schistosoma mansoni. Bull World Health Organ (1979) 57(5):781-785.
46. Santos AT, Blas BL, Nosenas JS, Portillo GP, Ortega OM, Hayashi M, Boehme K: Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. Bull World Health Organ (1979) 57(5):793-799.
47. Hagan P, Appleton CC, Coles GC, Kusel JR, Tchuem-Tchuenté L-A: Schistosomiasis control: Keep taking the tablets. Trends Parasitol (2004) 20(2):92-97.
48. Fenwick A, Webster JP: Schistosomiasis: Challenges for control, treatment and drug resistance. Curr Opin Infect Dis (2006) 19(6):577-582.
49. King CH, Sturrock RF, Kariuki HC, Hamburger J: Transmission control for schistosomiasis - why it matters now. Trends Parasitol (2006) 22(12):575-582. •• An excellent paper thinking beyond chemotherapy, discussing the optimization of schistosomiasis control using new monitoring tools and effective transmission containment.
50. Cioli D, Pica-Mattoccia L: Praziquantel. Parasitol Res (2003) 90(Supp 1):S3-9.
51. Keiser J, El Ela NA, El Komy E, El Lakkany N, Diab T, Chollet J, Utzinger J, Barakat R: Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model. Am J Trop Med Hyg (2006) 75(2):287-291.
52. Hsu E: The history of qing hao in the Chinese materia medica. Trans R Soc Trop Med Hyg (2006) 100(6):505-508.
53. Jiang JB, Li GQ, Guo XB, Kong YC, Arnold K: Antimalarial activity of mefloquine and qinghaosu. Lancet (1982) 320(8293):285-288.
54. Li Y, Wu YL: An over four millennium story behind qinghaosu (artemisinin) - a fantastic antimalarial drug from a traditional Chinese herb. Curr Med Chem (2003) 10(21):2197-2230.
55. China Cooperating Research Group on Qinghaosu and its Derivatives as Antimalarials: Clinical studies on the treatment of malaria with qinghaosu and its derivatives. J Tradit Chin Med (1982) 2(1):45-50.
56. Ashley EA, White NJ: Artemisinin-based combinations. Curr Opin Infect Dis (2005) 18(6):531-536.
57. Mutabingwa TK: Artemisinin-based combination therapies (ACTs): Best hope for malaria treatment but inaccessible to the needy! Acta Trop (2005) 95(3):305-315.
58. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, Dong YX, Dorn A, Hunziker D, Matile H et al: Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 430(7002):900-904. •• An important paper summarizing the multidimensional lead identification and optimization process of the antimalarial 1,2,4-trioxolanes.
59. Dong Y, Chollet J, Matile H, Charman SA, Chiu FC, Charman WN, Scorneaux B, Urwyler H, Santo Tomas J, Scheurer C, Snyder C et al: Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: Charting a workable structure-activity relationship using simple prototypes. J Med Chem (2005) 48(15):4953-4961.
60. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE et al: Averting a malaria disaster. Lancet (1999) 353(9168):1965-1967. •• An important and influential viewpoint advocating the use of ACTs in order to avoid or delay parasite drug resistance.
61. White N: Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci (1999) 354(1384):739-749.
62. Haynes RK: From artemisinin to new artemisinin antimalarials: Biosynthesis, extraction, old and new derivatives, stereochemistry and medicinal chemistry requirements. Curr Top Med Chem (2006) 6(5):509-537.
63. Hastings IM, Watkins WM, White NJ: The evolution of drug-resistant malaria: The role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci (2002) 357(1420):505-519.
64. Olliaro PL, Taylor WR: Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review. J Postgrad Med (2004) 50(1):40-44.
65. Meshnick SR: Artemisinin: Mechanisms of action, resistance and toxicity. Int J Parasitol (2002) 32(13):1655-1660.
66. Eckstein-Ludwig U, Webb RJ, Van Goethem IDA, East JM, Lee AG, Kimura M, O'Neill PM, Bray PG, Ward SA, Krishna S: Artemisinins target the SERCA of Plasmodium falciparum. Nature (2003) 424(6951):957-961.
67. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE: Current perspectives on the mechanism of action of artemisinins. Int J Parasitol (2006) 36(14):1427-1441. •• An excellent review of the possible mechanisms of action of artemisinins against malaria, presenting evidence for each mechanism of action suggested.
68. Chen DJ, Fu LF, Shao PP, Wu FZ, Fan CZ, Shu H, Ren CX, Sheng XL: Experimental studies on antischistosomal activity of qinghaosu. Zhong Hui Yi Xue Zha Zhi (1980) 60(7):422-425.
69. Le W, You J, Yang Y, Mei J, Guo H, Yang H, Zang C: Studies on the efficacy of artemether in experimental schistosomiasis. Acta Pharmaceut Sin (1982) 17(3):187-193.
70. Le WJ, You JQ, Mei JY: Chemotherapeutic effect of artesunate in experimental schistosomiasis. Acta Pharmaceut Sin (1983) 18(8):619-621.
71. Xiao SH, Catto BA: In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob Agents Chemother (1989) 33(9):1557-1562.
72. Xiao SH, Utzinger J, Chollet J, Endriss Y, N'Goran EK, Tanner M: Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int J Parasitol (2000) 30(9):1001-1006.
73. Jiraungkoorskul W, Sahaphong S, Sobhon P, Riengrojpitak S, Kangwanrangsan N: Effects of praziquantel and artesunate on the tegument of adult Schistosoma mekongi harboured in mice. Parasitol Int (2005) 54(3):177-183.
74. Xiao SH, Guo J, Chollet J, Wu JT, Tanner M, Utzinger J: Effect of artemether on Schistosoma mansoni: Dose-efficacy relationship, and changes in worm morphology and histopathology. Chin J Parasitol Parasit Dis (2004) 22(3):148-153.
75. Xiao SH, Tanner M, Shen BG, Utzinger J, Chollet J: Effect of artemether on the tegument of adult Schistosoma haematobium recovered from mice. Chin J Parasitol Parasit Dis (2006) 24(6):425-432.
76. Xiao SH, Utzinger J, Shen BG, Tanner M, Chollet J: Ultrastructral alterations of adult Schistosoma haematobium harbored in mice following artemether administration. Chin J Parasitol Parasit Dis (2006) 24(5):321-328.
77. Shaohong L, Kumagai T, Qinghua A, Xiaolan Y, Ohmae H, Yabu Y, Siwen L, Liyong W, Maruyama H, Ohta N: Evaluation of the anthelmintic effects of artesunate against experimental Schistosoma mansoni infection in mice using different treatment protocols. Parasitol Int (2006) 55(1):63-68.
78. Xiao SH, Chollet J, Utzinger J, Matile H, Mei JY, Tanner M: Artemether administered together with haemin damages schistosomes in vitro. Trans R Soc Trop Med Hyg (2001) 95(1):67-71.
79. Xiao SH, Wu YL, Tanner M, Wu WM, Utzinger J, Mei JY, Scorneaux B, Chollet J, Zhai Z: Schistosoma japonicum: In vitro effects of artemether combined with haemin depend on cultivation media and appraisal of artemether products appearing in the media. Parasitol Res (2003) 89(6):459-466.
80. Kruse HP, Liu F, Gatto C, Williams DL: Are SERCAs the target of artemisinin activity against Schistosoma mansoni? Am J Trop Med Hyg (2005) 73(6):Abs 102.
81. Xu M, Zhang S, Li S, Wang T, Chen J, Ou N, Fang G, Wang Q, Li J, Zhang X: Field application of artesunate in prophylaxis of schistosomiasis: An observation of 346 cases. Chin J Schisto Cont (1995) 7(6):323-327.
82. Li SW, Wu LJ, Liu ZD, Hu LS, Xu PS, Xuan YX, Liu YM, Liu X, Fan JT: Studies on prophylactic effect of artesunate on schistosomiasis japonica. Chin Med J (1996) 109(11):848-853.
83. Zhang SJ, Lin DD, Liu YM, Liu HY, Liu ZD, Hu LS, Ga ZL, Xu MS, Yi ZH, Wu LJ: Clinical trials on preventive effect of artesunate on schistosomiasis japonica. Mod Diagn Treat (2000) 11(2):68-72.
84. Li HY, Liu ZD, Hu LS, Liu YM, Hu F, Chen YH, Li SW, Wu LJ, Xu PS, Xuan YX: Observation on the prevention of schistosomiasis japonica by administration of artesunate long-term. Chin J Parasitol Parasit Dis (1999) 12(3):214-215.
85. Xu MS, Zhang SQ, Li SW, Wang TP, Chen JR, Ou N, Fang GR, Wang QZ, Li JT, Zhang XS: Field application of oral artesunate for preventing Schistosoma japonicum infection. Chin J Parasitol Parasit Dis (1999) 17(4):241-243.
86. Lu GY, Lin GJ, Sun MX, Cui JF, Wu QZ, Li J-S: Probe on scheme with oral artesunate protecting people from infection of schistosome. Chin J Parasitol Parasit Dis (2000) 13(3):212-214.
87. Tian ZY, Liu DS, Xiao ZW, Zhou YC, Qu GS, Yao XM, Zhang XY: A cost-effect study of artesunate in the prophylaxis of schistosomiasis in an endemic area. Chin J Schisto Cont (2001) 13(5):299-300.
88. Xu MS: The effect analysis of using artesunate to prevent schistosome infection in the field. Chin J Parasitol Parasit Dis (2001) 14(1):26-27.
89. Xiao SH, Wang JL, Wang CZ, Chu B, Yang H, Liu YH, Zheng J, Chen MG: Protection of the residents from schistosome infection using oral artemether in mountainous endemic area. Chin J Parasitol Parasit Dis (1996) 14(1):11-14.
90. Xiao SH, Shi ZG, Zhuo SJ, Wang CZ, Zhang ZG, Chu B, Zhen J, Chen MG: Field studies on the preventive effect of oral artemether against schistosomal infection. Chin Med J (1996) 109(4):272-275.
91. Tian ZY, Xiao SH, Xiao JW, Zhou YC, Liu DH, Zheng J, Chen MG, Qu GH, Zhang XY, Yao XM: Reduction of Schistosoma japonicum infection in an endemic area in islet with embankment after prophylaxis with oral artemether throughout the transmission season. Chin J Parasitol Parasit Dis (1997) 15(4):208-211.
92. Wang JL, Xiao SH, Yang Z, Wang MK, Yang H, Liu YH, Zhou GS, Zhen J, Chen MG: Effect of oral artemether in controlling schistosomiasis in Yunnan mountainous endemic area. Chin J Parasitol Parasit Dis (1997) 15:138-142.
93. Xu MS, Xiao SH, Song Q, Tao CG, Xia CG, Wang H, Chen MG, Zheng J, Bu CH, Hu FY: Observation on the effect of artemether on controlling schistosomiasis japonica in an endemic area of marshland. Chin J Parasitol Parasit Dis (1997) 15(4):212-215.
94. Song Y, Xiao SH, Wu W, Zhang S, Xie HQ, Xu XP, Hu XY, Cui Q, Chen MG, Zheng J: Preventive effect of artemether on schistosome infection. Chin Med J (1998) 111(2):123-127.
95. Li YS, Chen HG, He HB, Hou XY, Ellis M, McManus DP: A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop (2005) 96(2-3):184-190.
96. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao SH, Tanner M: Oral artemether for prevention of Schistosoma mansoni infection: Randomised controlled trial. Lancet (2000) 355(9212):1320- 1325.
97. N'Goran EK, Utzinger J, Gnaka HN, Yapi A, N'Guessan NA, Kigbafori SD, Lengeler C, Chollet J, Xiao SH, Tanner M: Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am J Trop Med Hyg (2003) 68(1):24-32.
98. Borrmann S, Szlezák N, Faucher J-F, Matsiegui P-B, Neubauer R, Binder RK, Lell B, Kremsner PG: Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: A double-blind, randomized, placebo-controlled study. J Infect Dis (2001) 184(10):1363-1366.
99. De Clercq D, Vercruysse J, Kongs A, Verlé P, Dompnier JP, Faye PC: Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Trop (2002) 82(1):61-66.
100. Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC: Efficacy of artesunate in the treatment of urinary schistosomiasis, in an endemic community in Nigeria. Ann Trop Med Parasitol (2004) 98(5):491-499.
101. De Clercq D, Vercruysse J, Verlé P, Niasse F, Kongs A, Diop M: Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal. Trans R Soc Trop Med Hyg (2000) 94(1):90-91.
102. Xiao SH, Utzinger J, Chollet J, Tanner M: Effect of artemether administered alone or in combination with praziquantel to mice infected with Plasmodium berghei or Schistosoma mansoni or both. Int J Parasitol (2006) 36(8):957-964.
103. Boulanger D, Dieng Y, Cisse B, Remoue F, Capuano F, Dieme J-L, Ndiaye T, Sokhna C, Trape J-F, Greenwood B, Simondon F: Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans R Soc Trop Med Hyg (2007) 101(2)113-116.
104. Keiser J, Utzinger J: Emerging foodborne trematodiasis. Emerg Infect Dis (2005) 11(10):1507-1514.
105. Lun ZR, Gasser RB, Lai DH, Li AX, Zhu XQ, Yu XB, Fang YY: Clonorchiasis: A key foodborne zoonosis in China. Lancet Infect Dis (2005) 5(1):31-41. • An important review summarizing the geographic distribution, epidemiology, pathogenesis and diagnosis of clonorchiasis. This review also makes some recommendations for future research.
106. Keiser J, Brun R, Fried B, Utzinger J: Trematocidal activity of praziquantel and artemisinin derivatives: In vitro and in vivo investigations with adult Echinostoma caproni. Antimicrob Agents Chemother (2006) 50(2):803-805. • This is the first report of the in vivo activity of artemisinins on an intestinal fluke. High doses of artesunate, artemether and artemisinin were required to achieve 99 to 100% worm burden reductions in mice.
107. Keiser J, Xiao SH, Tanner M, Utzinger J: Artesunate and artemether are effective fasciolicides in the rat model and in vitro. J Antimicrob Chemother (2006) 57(6):1139-1145.
108. Keiser J, Xiao SH, Xue J, Chan ZS, Odermatt P, Tesana S, Tanner M, Utzinger J: Effect of artesunate and artemether against Clonorchis sinensis and Opisthorchis viverrini in rodent models. Int J Antimicrob Agents (2006) 28(4):370-373.
109. Chen RX, Qu ZQ, Zeng MG, Li JY: Effect of qinghaosu and its derivatives on Clonorchis sinensis in rats. Bull Pharm (1983) 18(7):410-411.
110. Tinga N, De NV, Vien HV, Chau LV, Toan ND, Kager PA, de Vries PJ: Little effect of praziquantel or artemisinin on clonorchiasis in Northern Vietnam: A pilot study. Trop Med Int Health (1999) 4(12):814-818.
111. Shoeb HA, Tawfik AF, Shibl AM, el-Feraly FS: Antimicrobial activity of artemisinin and its derivatives against anaerobic bacteria. J Chemother (1990) 2(6):362-367.
112. Kaptein SJ, Efferth T, Leis M, Rechter S, Auerochs S, Kalmer M, Bruggeman CA, Vink C, Stamminger T, Marschall M: The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res (2006) 69(2):60-69.
113. Efferth T: Mechanistic perspectives for 1,2,4-trioxanes in anticancer therapy. Drug Resist Updat (2005) 8(1-2):85-97. •• An excellent paper summarizing the activities and mechanism of action of artemisinins on cancer cells. Artesunate was highly active against various human cancer cells, including leukemia and colon cancer cells, triggering a multifactorial cellular response.
114. Paik IH, Xie S, Shapiro TA, Labonte T, Narducci Sarjeant AA, Baege AC, Posner GH: Second generation, orally active, antimalarial, artemisinin-derived trioxane dimers with high stability, efficacy, and anticancer activity. J Med Chem (2006) 49(9):2731-2734.
115. Lai H, Singh NP: Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett (2006) 231(1):43-48.
116. Disbrow GL, Baege AC, Kierpiec KA, Yuan H, Centeno JA, Thibodeaux CA, Hartmann D, Schlegel R: Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res (2005) 65(23):10854-10861.
117. Keiser J, Utzinger J, Tanner M, Dong Y, Vennerstrom JL: The synthetic peroxide OZ78 is effective against Echinostoma caproni and Fasciola hepatica. J Antimicrob Chemother (2006) 58(6):1193-1197.
118. Xiao SH, Chollet J, Weiss NA, Bergquist RN, Tanner M: Preventive effect of artemether in experimental animals infected with Schistosoma mansoni. Parasitol Int (2000) 49(1):19-24.
119. Xiao SH, Shen BG, Horner J, Catto BA: Tegument changes of Schistosoma japonicum and Schistosoma mansoni in mice treated with artemether. Acta Pharmacol Sin (1996) 17(6):535-537.
120. Xiao SH, Shen BG, Catto BA: Effect of artemether on ultrastructure of Schistosoma japonicum. Chin J Parasitol Parasit Dis (1996) 14(3):181-187.
121. Xiao SH, Shen BG, Chollet J, Utzinger J, Tanner M: Tegumental changes in adult Schistosoma mansoni harbored in mice treated with artemether. J Parasitol (2000) 86(5):1125-1132.
122. Xiao SH, Shen BG, Utzinger J, Chollet J, Tanner M: Ultrastructural alterations in adult Schistosoma mansoni caused by artemether. Mem Inst Oswaldo Cruz (2002) 97(5):717-724.